Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.

June 5, 2017
PresentationFiclatuzumab

ASCO 2017: CyFi: A phase I study exploring the role of cMET pathway inhibition with ficlatuzumab (Fi) combined with high-dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML)

July 20, 2016
PublicationFiclatuzumab

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma

Authors: Tony Shu Kam Mok, Sarayut Lucien Geater, Wu-Chou Su, Eng-Huat Tan, James Chi-Hsin Yang, Gee-Chen Chang, May Han, Philip Komarnitsky, Francis Payumo, Jennifer E. Garrus, Sandra Close, Keunchil Park. Click here for link to article.

September 29, 2014
PresentationFiclatuzumab

ESMO 2014: Efficacy analysis of gefitinib +/- ficlatuzumab in serum proteomic-based subgroups of patients with previously untreated lung adenocarcinoma

September 30, 2012
PresentationFiclatuzumab

ESMO 2012: Pharmacodynamic–pharmacokinetic study of ficlatuzumab, a monoclonal antibody directed to the hepatocyte growth factor (HGF), in patients with advanced solid tumors who have liver metastases

September 29, 2012
PresentationFiclatuzumab

ESMO 2012: A randomized phase 2 study with exploratory biomarker analysis of ficlatuzumab, a humanized hepatocyte growth factor (HGF) inhibitory monoclonal antibody, in combination with gefitinib versus gefitinib alone in Asian patients with lung adenocarcinoma

June 6, 2011
PresentationFiclatuzumab

ASCO 2011: Phase 2 Study of Ficlatuzumab (AV-299), an Anti-Hepatocyte Growth Factor Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With Non–Small Cell Lung Cancer

1 2 3 4

Looking for medical information? Contact our Medical Information Team at

AVEOmedicalinformation@aveooncology.com.